ライフサイエンスコーパス: gal

1 different oil loadings (100, 333, and 1,000 gal acre(-1)) and mixing regimes (fully, moderately, and

2 e initial oil loading was increased to 1,000 gal acre(-1).

3 ing 1/8 teaspoon (or 8 drops) of bleach to 1 gal of water.

4 ng cell surface glycoconjugates, galectin-1 (gal-1) is involved in cell adhesion and migration proces

5 Galectin-1 (gal-1), a special lectin with high affinity to beta-gala

6 ted the therapeutic potential of galectin-1 (gal-1), an endogenous lectin that in some autoimmune dis

7 estigated the ability of soluble galectin-1 (gal-1), an endogenous lectin that promotes T cell apopto

8 ox assay showed no major toxicity at the 100 gal acre(-1) loading.

9 ion in water-use intensity by 40% (2000-1200 gal/ft; 2.5-1.5 m(3)/m).

10 generators with mostly cooling towers (0.19 gal/kWh) being 63% lower than that of traditional coal,

11 luent samples for the concrete, 5 gal, and 2 gal filters, respectively, had E. coli concentrations of

12 d two scaled-down versions that use a 5 or 2 gal bucket as the casing material.

13 h) of greenhouse gas (GHG) emissions and 224 gal/MWh (80% CI: 185-305 gal/MWh) of freshwater consumpt

14 Galectin-3 (gal-3) is a beta-galactoside-binding lectin expressed in

15 Galectin-3 (gal-3), the only antiapoptotic member of the galectin fa

16 ckout (DKO)] that produce the gal-alpha(1,3)-gal and N-glycolylneuraminic acid xenoantigens reduces h

17 Porcine RMEC expressed gal-alpha(1,3)-gal, N-glycolylneuraminic acid, and Dolichos biflorus ag

18 Inhibition of Tim-3/gal-9 binding by infusion of a Tim-3-Ig fusion protein o

19 When the Tim-3/gal-9 pathway engagement was augmented using gal-9 trans

20 t to show that although the absence of Tim-3/gal-9 pathway interactions augments systemic GVHD, concu

21 Paradoxically, when Tim-3/gal-9 was inhibited in the absence of donor T-regulatory

22 ) emissions and 224 gal/MWh (80% CI: 185-305 gal/MWh) of freshwater consumption.

23 se of the moderately mixed microcosms at 333 gal acre(-1) and was maintained at moderate levels (EC(5

24 rometric microcosms at an oil loading of 333 gal acre(-1) (0.31 L m(-2)) and BHT concentrations rangi

25 72% of effluent samples for the concrete, 5 gal, and 2 gal filters, respectively, had E. coli concen

26 e generators with mostly cooling ponds (0.52 gal/kWh).

27 with mean Bakken water use/well (2.0 x 10(6) gal/well) about half that in the Eagle Ford, and a third

28 nsity is estimated to be between 1.8 and 2.7 gal/MMBtu and is similar to surface coal mining.

29 thogenic T cells, and its ligand galectin-9 (gal-9) is up-regulated in inflamed tissues.

30 times from 2005-2014, totaling 24.5 x 10(9) gal (93 x 10(9) L) for approximately 10140 wells.

31 ditional wells and related HF of 265 x 10(9) gal and FP of 85 x 10(9) gal.

32 d HF of 265 x 10(9) gal and FP of 85 x 10(9) gal.

33 ing access of up to approximately 33 x 10(9) gal/year (125 x 10(9) L/year) from Lake Sakakawea, expan

34 Since the alpha gal epitope is found on gut enterobacteria, it has been

35 Alpha-gal epitopes were detected by immunoblotting on antiveno

36 Alpha-gal is a potential target of IgE-mediated reactivity to

37 Alpha-gal-sIgE levels were assessed by ImmunoCAP assay.

38 Alpha-gal-sIgE positivity was associated with total IgE levels

39 Vaccination against alpha-gal confers sterile protection against malaria in mice,

40 y suggests that alpha-gal liposome and alpha-gal nanoparticle treatment may enhance wound healing in

41 h-titer IgE antibodies for Ara h 2 and alpha-gal, respectively.

42 O86:B7 express alpha-gal and that anti-alpha-gal Abs are associated with protection against malaria t

43 Anti-alpha-gal Abs target Plasmodium sporozoites for complement-med

44 nt mice, which produce protective anti-alpha-gal Abs when colonized by E. coli O86:B7.

45 and allowed for the production of anti-alpha-gal antibodies (Abs) in humans, confers protection again

46 By contrast, an anti-alpha-gal IgM antibody response was shown to protect against m

47 Neither the depletion of autologous alpha-gal-specific IgG Ab nor the addition of alpha-gal-specif

48 hesizes a carbohydrate antigen called "alpha-gal epitope." The alpha-gal epitope is present in large

49 of the Fc portion of anti-Gal coating alpha-gal liposomes to FcgammaRs on recruited macrophages may

50 Their enhanced alpha-gal-specific IgE levels are accompanied by high levels o

51 alalpha1-3Galbeta1-4GlcNAc-R epitopes (alpha-gal liposomes) on wounds may accelerate the healing proc

52 gut pathobiont E. coli O86:B7 express alpha-gal and that anti-alpha-gal Abs are associated with prot

53 ion of mammalian xenografts expressing alpha-gal epitopes in humans, apes, and Old World monkeys.

54 Antivenoms were screened for alpha-gal epitopes via immunoblot and in comparison with cetux

55 loyees and hunters, the odds ratio for alpha-gal-sIgE positivity was 2.48 compared to the residential

56 itopes, galactose-alpha-1,3-galactose (alpha-gal) and Neu5Gc-alpha-2-6-galactose (Neu5Gc) have been s

57 nut and galactose alpha-1,3-galactose (alpha-gal) are characterized by high- or very high-titer IgE a

58 charide galactose-alpha-1,3-galactose (alpha-gal) are common in the southeastern United States.

59 IgG to galactose-alpha-1,3-galactose (alpha-gal) are highly abundant natural antibodies (Ab) in huma

60 ific to galactose-alpha-1,3-galactose (alpha-gal) are responsible for a delayed form of anaphylaxis t

61 hydrate galactose-alpha-1,3-galactose (alpha-gal) is known to induce delayed anaphylaxis against mamm

62 charide galactose-alpha-1,3-galactose (alpha-gal).

63 pitope, galactose-alpha-1,3-galactose (alpha-gal).

64 (IgG) that recognizes the heterophilic alpha-gal epitope.

65 c patients showed significantly higher alpha-gal-specific IgG1 and IgG3 Ab than nonallergic individua

66 prevalence of alpha-gal-specific IgE (alpha-gal-sIgE) positivity varies between different population

67 Moreover, scar formation in alpha-gal liposome-treated wounds is much lower than in physio

68 ld-type mice, these knockout mice lack alpha-gal epitopes and can produce the anti-Gal Ab.

69 mans, apes, and Old World monkeys lack alpha-gal epitopes and naturally produce an antibody called th

70 s transplanted with pig organs lacking alpha-gal epitopes have suggested that anti-non gal antibodies

71 ed that the antivenoms contained lower alpha-gal contents than cetuximab.

72 od allergies and distinct from natural alpha-gal IgG responses in nonallergic individuals.

73 explained by the delayed expression of alpha-gal due to digestive processes.

74 Establishing the source of alpha-gal in arthropod vectors and the immune response to vect

75 Additional sonication of alpha-gal liposomes resulted in their conversion into submicro

76 The identification of alpha-gal syndrome in patients with IA supports the need for r

77 a population with a high prevalence of alpha-gal-sIgE positivity and carry a considerable risk of red

78 To investigate the prevalence of alpha-gal-sIgE positivity in a population of forest service em

79 The prevalence of alpha-gal-sIgE positivity in the current and historic cohort w

80 he study population, the prevalence of alpha-gal-sIgE-positive (>/=0.10 kUA /L) individuals was 35.0%

81 The prevalence of alpha-gal-sIgE-positive individuals was compared with a matche

82 The reported prevalence of alpha-gal-specific IgE (alpha-gal-sIgE) positivity varies betw

83 al-specific IgG Ab nor the addition of alpha-gal-specific IgG Ab from nonallergic individuals changed

84 vels are accompanied by high levels of alpha-gal-specific IgG1 devoid of IgE-blocking activity.

85 showed significantly higher levels of alpha-gal-specific IgG4 Ab.

86 d the protective or allergic effect of alpha-gal.

87 o its ligand, the alpha-gal epitope on alpha-gal liposomes would induce local activation of complemen

88 rate Galalpha1-3Galbeta1-(3)4GlcNAc-R (alpha-gal) following a tick bite was associated with allergies

89 of the Galalpha1-3Galbeta1-4GlcNAc-R (alpha-gal) glycan and allowed for the production of anti-alpha

90 n their conversion into submicroscopic alpha-gal nanoparticles.

91 The study suggests that alpha-gal liposome and alpha-gal nanoparticle treatment may en

92 r serum IgE antibodies directed to the alpha-gal epitope are associated with hypersensitivity to equi

93 ntigen called "alpha-gal epitope." The alpha-gal epitope is present in large numbers on cell membrane

94 Ig in humans) bound to its ligand, the alpha-gal epitope on alpha-gal liposomes would induce local ac

95 IgG Ab that selectively recognize the alpha-gal epitope on BGG.

96 Once the alpha-gal epitope was eliminated, primates could produce the a

97 ests with cetuximab, which carries the alpha-gal epitope.

98 ion of primate populations lacking the alpha-gal epitope.

99 such reactions and characterized their alpha-gal-specific IgE and IgG responses in more detail.

100 These alpha-gal nanoparticles diffused more efficiently in wounds an

101 several hours in patients with IgE to alpha-gal (galactose-alpha-1,3-galactose) have been reported.

102 tients with specific IgE antibodies to alpha-gal and 10 controls.

103 association between IgE antibodies to alpha-gal and asthma (odds ratios, 1.04 and 0.75, respectively

104 al reactions but lower specific IgE to alpha-gal and higher serum tryptase levels, reflective of the

105 mammalian meat in subjects with IgE to alpha-gal and to monitor ex vivo for the appearance of markers

106 use of anaphylaxis, where reactions to alpha-gal are delayed and thus may be overlooked.

107 antibody" which binds specifically to alpha-gal epitopes and which is the most abundant antibody in

108 Ten of 12 subjects with IgE to alpha-gal had clinical evidence of a reaction during the food

109 inia with high-titer IgE antibodies to alpha-gal had normal lung function, low levels of exhaled nitr

110 IgE to alpha-gal has been associated with 2 distinct forms of anaphyl

111 nt cause, of IgE antibody responses to alpha-gal in the southern, eastern, and central United States;

112 the specific IgE antibody response to alpha-gal will be an important aspect to address as this area

113 test results in patients with sIgE to alpha-gal.

114 A), six (9%) were found to have IgE to alpha-gal.

115 ed basophils from patients with IgE to alpha-gal.

116 ensitization source, as ticks transfer alpha-gal in their saliva to a host during a bite.

117 f monoclonal antibodies (mAbs) , while alpha-gal attached to Fc glycans was not.

118 of excisional skin wounds treated with alpha-gal liposomes in these mice is twice as fast as that of

119 eriments, sera were pre-incubated with alpha-gal or protein G to deplete IgG Ab. alpha-Gal-specific I

120 e recent finding is that patients with alpha-gal syndrome do not have detectable IgG4 to the oligosac

121 eas the prevalence of individuals with alpha-gal-sIgE levels >/=0.35 kUA /L was 19.3%.

122 found in 8.6% of the participants with alpha-gal-sIgE levels >/=0.35 kUA /L.

123 ly abolished after pre-incubation with alpha-gal.

124 tivity to antivenom is associated with alpha-gal.

125 were then performed between BM12 donors and gal-3 null recipients on a C57BL/6 background.

126 ns show distinct differences in the glc- and gal-PAS systems that correlate well with observed differ

127 s reliable representations of novel glc- and gal-PASs.

128 Anti-gal antibodies in patients with liver cirrhosis were red

129 risingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their abi

130 with increased levels of this modified anti-gal antibody had increased levels of markers of bacteria

131 The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrho

132 bacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased ba

133 es Wnt/beta-catenin signaling, using the BAT-gal transgenic reporter.

134 e producing CD4(+) T cells specific for beta gal (beta galTCR).

135 ) for expression of beta-galactosidase (beta gal) on the retinal photoreceptor cell arrestin promoter

136 ells in mice with retinal expression of beta gal and inhibited the ear-swelling assay for delayed typ

137 D25(-) beta galTCR T cells into retinal beta gal Tg mice on the Rag(-/-) background led to regulatory

138 (+)4(+)25(+) T cells from naive retinal beta gal(+) donors.

139 Experiments that removed the beta gal(+) retina by enucleation showed that subsequent deve

140 ssed development of immune responses to beta gal following systemic immunization with beta gal.

141 al following systemic immunization with beta gal.

142 ither adenovirus Ang-1 (Ad-Ang-1) or Ad-beta-gal systemically immediately after ligation of the left

143 sity compared with pigs treated with Ad.beta-gal was found at 3 months and suggests an angiogenic rol

144 nt (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanced ca

145 g for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

146 4.2% (P=0.004) in pigs treated with Ad.beta-gal.

147 All beta-gal-positive cells exhibited abundant cytoplasm, a typic

148 olated cells were evaluated for GFP and beta-gal as well as expression of alpha-smooth muscle actin (

149 untreated liver expressed both GFP and beta-gal with a fibroblast-like morphological change but lack

150 er showed double-positivity for GFP and beta-gal.

151 ed the retinal location of ANT and ANT1-beta-gal reporter protein, mitochondrial activity with cytoch

152 growth arrest and senescence-associated beta-gal (SA-beta-gal) activity.

153 cuous or self-specific knocked in BCRs, beta-gal was preferentially expressed in pre-B cells from the

154 erived cells are permanently labeled by beta-gal and type I collagen-expressing cells are labeled by

155 the inhibitory molecule daunorubicin by beta-gal.

156 ontrast, LECs do not present endogenous beta-gal in the context of MHC-II molecules to beta-gal-speci

157 xperiments showed that the newly formed beta-gal(+) SMC were not derived from circulating bone marrow

158 beta-galactosidase (beta-gal) and beta-glucuronidase (beta-glucur) are both produ

159 the procedure with beta-galactosidase (beta-gal) as the detection enzyme.

160 of an axon-targeted beta-galactosidase (beta-gal) from such vectors supports mapping specific commiss

161 to release endemic beta-galactosidase (beta-gal) from the bound bacterial cells; (3) the release of

162 imals, staining for beta-galactosidase (beta-gal) identifies cells in which NF-kappaB has been activa

163 ize heat-aggregated beta-galactosidase (beta-gal) in the absence of the Hsp70 system.

164 monstrate that when beta-galactosidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells

165 PROM was fused to a beta-galactosidase (beta-gal) reporter.

166 ressing ROSA26 stop beta-galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) green fluoresc

167 en egg lysozyme and beta-galactosidase (beta-gal), demonstrating adaptive immune responses against so

168 us (rAd.A20) or rAd.beta-galactosidase (beta-gal), implanted, harvested 4 weeks after transplantation

169 the omega-domain of beta-galactosidase (beta-gal).

170 operon encoding for beta-galactosidase (beta-gal).

171 reased expression of beta-galactosidase(beta-gal) plasmid in rat brain tissue in comparison to the si

172 t IRF4 transcripts were up-regulated in beta-gal(+) pre-B cells.

173 ace conditioning, we observed increased beta-gal staining in the nucleus accumbens (NAC) shell and do

174 The endogenous and phage-induced beta-gal was detected using the electrochemical method with 4

175 release of the endogenous intracellular beta-gal from E. coli following infection.

176 aB alpha gene was replaced with a lacZ (beta-gal) reporter complementary DNA (cDNA; IkappaB alpha(+/l

177 sidase (beta-gal) is expressed in LECs, beta-gal-specific CD8 T cells undergo deletion via the PD-1/P

178 rphic mice expressing a promoter-linked beta-gal reporter to show that inflammatory colitis suppresse

179 We cloned VLRB binders of lysozyme, beta-gal, cholera toxin subunit B, R-phycoerythrin, and B-tri

180 erized by a large flat cell morphology, beta-gal staining and irreversible loss of regenerative (i.e.

181 bility to trigger the overexpression of beta-gal during the infection of E. coli.

182 ion of E. coli by (1) overexpression of beta-gal in E. coli during the specific infection and (2) rel

183 el of expression of the omega-domain of beta-gal in the model K12 strains allowed us to detect, on av

184 The RF scar area and the area of beta-gal staining were measured and normalized to LV area (pl

185 und bacterial cells; (3) the release of beta-gal was detected using chlorophenol red-beta-d-galactopy

186 nary PW1(+) cells and the proportion of beta-gal(+) vascular SMC were increased, indicating a recruit

187 this complementation-an active form of beta-gal-was detected colorimetrically, and the high level of

188 s from yellow to red in the presence of beta-gal.

189 virus encoding for SCF (Ad.SCF, n=9) or beta-gal (Ad.beta-gal, n=6) into the infarct border area.

190 with antibodies against GFP, DsRed, or beta-gal using the method of immunolabeling-enabled three-dim

191 ng isolation, using R26R-EYFP and R26R (beta-gal) reporter mice, respectively.

192 ls in nontransduced, and rAd.A20 or rAd.beta-gal-transduced human SMC cultures after cytokine treatme

193 cence-associated beta-galactosidase (SA beta-gal) activity was observed in lymphomas from Emu-myc::p5

194 Ink4a), p21, senescence-associated (SA) beta-gal activity, and SA secretion of proinflammatory cytoki

195 With age, NSCs exhibited increased SA-beta-gal activity and decreased proliferation and pool size i

196 cence-associated beta-galactosidase (SA-beta-gal) activity and production of intracellular reactive s

197 cence-associated beta-galactosidase (SA-beta-gal) activity but an increase in adenosine triphosphate

198 ecies (iROS), SA-beta-galactosidase (SA-beta-gal) activity, and autofluorescence (AF) was assessed by

199 and senescence-associated beta-gal (SA-beta-gal) activity.

200 ns and significantly decreased iROS, SA-beta-gal, and AF normally induced by hyperoxic conditions.

201 sion was also confirmed both by in situ beta-gal staining and quantitative enzymatic activity assay i

202 scence (OIS) was demonstrated by strong beta-gal staining and absence of Ki-67 expression.

203 m agglutinin (WGA) and an axon-targeted beta-gal supports mapping both specific projections of the tr

204 The beta-gal catalyzed PAPG to an electroactive species p-aminoph

205 Here, we show, using the beta-gal gene as a reporter, that amber, ochre, and opal supp

206 M9PROM activation was localized through beta-gal staining.

207 l in the context of MHC-II molecules to beta-gal-specific CD4 T cells.

208 Importantly, LECs transfer beta-gal to dendritic cells, which subsequently present it to

209 (-/-)) created by replacing exon 2 with beta-gal and neo cassettes.

210 h observed differences in solubility between gal-PASs and glc-PASs.

211 ning cost, for example, approximately 1 cent/gal for 95-RON E20 or 97-RON E30, and 3-5 cent/gal for 9

212 l for 95-RON E20 or 97-RON E30, and 3-5 cent/gal for 95-RON E10, 98-RON E20, or 100-RON E30.

213 heir flexibilities reported here for E. coli gal promoters may help construction of synthetic promote

214 hatase activity, while addition of exogenous gal-3 reduced phosphatase activity.

215 Porcine RMEC expressed gal-alpha(1,3)-gal, N-glycolylneuraminic acid, and Dolic

216 The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane

217 Our results suggest a potential role for gal-3 in CAI, and this represents a potentially exciting

218 Marmosets maintained on 30% galactose (gal)-rich diet for 2 years were monitored for retinal va

219 scherichia coli lactose (lac) and galactose (gal) operons precludes access to key recognition element

220 Glucose- (glc-) and galactose- (gal-) PAS 10-mer structures are synthesized and investig

221 sine kinase receptor (sFlt)-1, and galectin (gal)-3.

222 gas zones per well (4.7-4.9 x 10(6) gallons [gal]/well).

223 When Tim-3(+) T cells encounter high gal-9 levels, they are deleted.

224 Importantly, gal-1 reversed beta-cell autoimmunity and hyperglycemia

225 uced expression of interleukin-4 (P=0.02) in gal-3 null mice suggest possible mechanisms by which gal

226 verse fibrotic tissue, and mice deficient in gal-3 have reduced fibrosis in kidney, liver, and lung m

227 Furthermore, disease severity was greater in gal-1 knockout mice compared with their wild-type counte

228 ular atrophy (P<0.0001), and upregulation in gal-3 expression (P=0.002), compared with syngeneic cont

229 verall, our results provide new insight into gal-1 structure-function relationships and to protein-ca

230 Transplanting BM12 kidneys into gal-3 null mice resulted in significant preservation of

231 tic systemic clearance of (1)(8)F-FDGal (K*(+gal) from linear analysis of data (Gjedde-Patlak method)

232 Mean K*(+gal) determined from the PET study was 0.019 L of blood/

233 y characterize DNA loops induced by the lac, gal, and lambda repressors and (ii) understand the mecha

234 f the tagatose-6-phosphate (lac) and Leloir (gal) pathways was performed in strain UA159.

235 trated that in nonobese diabetic (NOD) mice, gal-1 therapy reduces significantly the amount of Th1 ce

236 MTS-gal is bound covalently, forming a disulfide bond with C

237 22 LacY in complex with covalently bound MTS-gal.

238 methanethiosulfonyl-galactopyranosides (MTS-gal), which behave as unique suicide substrates.

239 Anti-non gal antibodies are produced in xenograft recipients agai

240 ts indicated that the production of anti-non gal antibodies is much slower than that of the anti-Gal

241 ha-gal epitopes have suggested that anti-non gal antibodies mediate acute and chronic rejection of xe

242 Anti-non gal antibodies were found to be continuously produced as

243 not fully inhibit the production of anti-non gal antibodies.

244 Overcoming the anti-non gal antibody barrier will require immunosuppressive agen

245 ng leukocytes was unaltered by abrogation of gal-3, but reduced expression of YM1 (P=0.0001), a marke

246 Administration of gal-1 prevented the onset of hyperglycemia in NOD mice a

247 Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; r

248 The beneficial effects of gal-1 correlated with the ability of the lectin to trigg

249 The many effects of gal-1 treatment include reduction in the production of p

250 ation of CD45 is important for regulation of gal-3-mediated signaling.

251 to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity.

252 l tortuosity were observed in the retinas of gal-fed marmosets.

253 howed incipient microaneurysms in retinas of gal-fed marmosets.

254 The role of gal-3 in CAI is examined in this study.

255 l-1 and to derive solution NMR structures of gal-1 in the lactose-bound and unbound states.

256 resent study investigated transplantation of gal-1-secreting neural stem cell (s-NSC) into ischemic b

257 way to reduce disease by increasing Tim-3 or gal-9 engagement.

258 neuroprotection than non-engineered NSCs or gal-1-overexpressing (but non-secreting) NSCs.

259 Preventive gal-1 therapy shifted the composition of the insulitis i

260 Treatment with recombinant gal-1 significantly diminished stromal keratitis lesion

261 i cAMP-CRP (cAMP receptor protein) regulated gal promoters by in vitro transcription assays.

262 c DNA-binding proteins; i.e., lac repressor, gal repressor, and lambda O protein, are able to divide

263 Preliminary toxicity study for RG-(gal)(28)GSA using Balb/c mice reveal no toxic effects up

264 Evaluation of RG-(gal)(28)GSA, RG-(gal)(20)GSA, glucose-analogue RG-(glu)(28)GSA, and contr

265 Evaluation of RG-(gal)(28)GSA, RG-(gal)(20)GSA, glucose-analogue RG-(glu)(

266 An optical probe, RG-(gal)(28)GSA, was synthesized to improve the detection of

267 These data indicate that RG-(gal)(28)GSA can selectively target a variety of human ad

268 A promoter fusion reporter gene, rtaA:gal(u), is expressed in a subset of the ALCs that is dis

269 lower cup and the outer basal disk, the rtaA:gal(u) expressing cells preferentially populate the uppe

270 ed cell death, as demonstrated by the SAbeta-gal assay.

271 Using a combination of Salmon-gal and tetranitroblue tetrazolium, we were able to visu

272 Here, we show that Salmon-gal in combination with tetrazolium salts provides a mor

273 To accomplish this goal, secretory gal-1 was stably overexpressed in NE-4C neural stem cell

274 some of the GalR specific DNA binding sites (gal operators), we used the chromosome conformation capt

275 e gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the c

276 enescence-associated ss-galactosidase (SA-ss-gal), and p16(INK4a) were increased 2-, 8-, and 20-fold

277 data identify a novel role for cell-surface gal-3 and CD45 in DLBCL survival and suggest novel thera

278 activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activ

279 Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS

280 ther with recent findings demonstrating that gal-1 promotes binding of agonist tetramers to the TCR o

281 dge, our findings are the first to show that gal-1 treatment represents a useful approach to control

282 acterization of spontaneous mutations in the gal operon guided the discovery that bacteria transpose

283 two carbohydrate recognition domains of the gal-1 dimer with negative cooperativity, in that the fir

284 nes [double knockout (DKO)] that produce the gal-alpha(1,3)-gal and N-glycolylneuraminic acid xenoant

285 r modeling to investigate lactose binding to gal-1 and to derive solution NMR structures of gal-1 in

286 gal-9 pathway engagement was augmented using gal-9 transgenic recipients, GVHD lethality was slowed.

287 ll mice suggest possible mechanisms by which gal-3 may promote renal transplant fibrosis.

288 While gal-3 can localize to intracellular sites, gal-3 is secr

289 X-gal (5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside

290 X-gal analysis has shown strong beta-galactosidase activit

291 proximal promoter activity was analyzed by X-gal staining.

292 se in embryos at stages when the customary X-gal reaction failed to detect staining.

293 a gene-trap mouse model for PRCP deletion, X-gal staining was performed to further determine PRCP dis

294 Histochemical X-gal (5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside

295 le RTN region contained significantly more x-gal-labeled cells than the female RTN region.

296 No X-gal staining was observed in secretory stage ameloblasts

297 t with fibrotic septa and never overlapped X-gal-positive areas.

298 encoded by lacZ, is usually detected using X-gal in combination with ferric and ferrous ions.

299 distribution of PLAG1 in the testis using X-gal staining; (ii) transcriptomic consequences of PLAG1

300 yme was localised in germinated seeds with X-gal activity staining and shown to be expressed prominen